In the UK, hospital stays for people with bipolar disorder cost taxpayers £207 million ($324.2 million) a year, according to the research sponsored by AstraZeneca presented yesterday. The National Health Service spends just 7% (£25 million) of the total costs for bipolar disorder on medicines versus 60% on hospital admissions. The findings of the research are important as the NHS has been told to identify £15-20 billion of cost savings by the end of the 2013-14 financial year.
The research was led by Allan Young in collaboration with AstraZeneca. Prof Young, formerly of Newcastle University and currently of the University of British Columbia, said of the research: "The main reason for hospitalizations in bipolar disorder is relapses suffered by patients in which they experience extreme mood changes. There is evidence to suggest that a range of available treatments for bipolar disorder are able to reduce the risk of patients
'Spend to save' approach of new administration
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze